WealthPlan Investment Management LLC Takes Position in Perspective Therapeutics, Inc. (NYSE:CATX)

WealthPlan Investment Management LLC purchased a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 339,292 shares of the company’s stock, valued at approximately $4,530,000.

Other institutional investors have also made changes to their positions in the company. Sykon Capital LLC increased its position in shares of Perspective Therapeutics by 4.7% during the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after purchasing an additional 1,717 shares during the period. US Bancorp DE increased its position in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the period. nVerses Capital LLC bought a new stake in shares of Perspective Therapeutics during the third quarter valued at approximately $57,000. Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics during the third quarter valued at approximately $153,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics during the second quarter valued at approximately $117,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CATX. Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of Perspective Therapeutics in a research report on Thursday, October 24th. Truist Financial began coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Royal Bank of Canada reduced their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. UBS Group initiated coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $20.63.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $11.05 on Tuesday. Perspective Therapeutics, Inc. has a 52-week low of $2.20 and a 52-week high of $19.05. The firm has a fifty day simple moving average of $13.09.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million for the quarter. Equities research analysts expect that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.